Please select an option below to help us tailor your newsletter to best suit your content interests!
A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma: Substudy 02C
VIEW TRIAL ON CLINICALTRIALS.GOVMelanoma, Cutaneous Melanoma
Stage 3
Phase 2
Open to Enrollment
Neoadjuvant
Pembrolizumab, MK-7684, V937
Anti-PD-1, Anti-TIGIT, Oncolytic virus
David Portnoy, MD
Merck Sharp & Dohme Corp
Melanoma
A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy With Relatlimab and Nivolumab Fixed-dose Combination Versus Nivolumab Monotherapy After Complete Resection of Stage III-IV Melanoma
VIEW TRIAL ON CLINICALTRIALS.GOVMelanoma
Stage 3
Phase 3
Open to Enrollment
Adjuvant
Relatlimab, Nivolumab
LAG3 inhibitor, PD-1 inhibitor
David Portnoy
Bristol Myers Squibb
A Phase 1/2 open-lable rolling-arm umbrella platford design of investigational agents with or without pembrolizumab or pembrolizumab alone in participants with melanoma (KEYNOTE-U02): Substudy 02B.
VIEW TRIAL ON CLINICALTRIALS.GOVMelanoma, Cutaneous Melanoma
Stage 4
Phase 2
Open to Enrollment
1st Line, PD-1 naive
Multiple
David Portnoy, MD
Merck Sharp & Dohme Corp
Melanoma
A Phase 1/2 open-lable rolling-arm umbrella platford design of investigational agents with or without pembrolizumab or pembrolizumab alone in participants with melanoma (KEYNOTE-U02): Substudy 02A.
VIEW TRIAL ON CLINICALTRIALS.GOVMelanoma
Stage 4
Phase 2
Open to Enrollment
2nd Line (post PD-1)
Multiple
David Portnoy, MD
Merck Sharp & Dohme Corp
Melanoma
An open-label, multicenter, Phase 1/2 study of RP1 as a single agent and in combination with PD1 blockade in patients with solid tumors
VIEW TRIAL ON CLINICALTRIALS.GOVMelanoma, Skin Cancer, ocular melanoma, mucosal melanoma
Stage 4
Phase 2
Open to Enrollment
2nd
RP1 + nivolumab
Oncolytic virus
Ari VanderWalde, MD
Replimune Inc.
Melanoma
An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors
VIEW TRIAL ON CLINICALTRIALS.GOVNon-melanoma skin cancer, basal cell carcinoma, cutaneous squamous cell carcinoma, Merkel cell carcinoma,
Stage 4
Phase 2
Open to Enrollment
No prior PD-1
RP1, nivolumab
oncolytic virus (HSV), PD-1 inhibitor
Ari VanderWalde, MD
Replimune, Inc.
Basal cell carcinoma, cutaneous squamous cell carcinoma, Merkel cell carcinoma, basosquamous carcinoma, high-grade dermatofibroma protuberans, angiosarcoma of the skin, non-HIV-related Kaposi sarcoma, sebaceous gland carcinome, eccrine carcinomas
A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes.
VIEW TRIAL ON CLINICALTRIALS.GOVBreast, lung, colon, prostate, bladder, RCC, kidney, skin, melanoma, gastric, pancreatic, HCC, rectal, sarcoma, head and neck, esophagus, biliary tract
Stage 4
Phase 2
Open to Enrollment
Last line
nab-sirolimus
MTOR inhibitor
Dan Vaena, MD
Aadi Bioscience, Inc.
TSC1 or TSC2 alterations
A Phase 1/2, Open Label, Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors
VIEW TRIAL ON CLINICALTRIALS.GOVMelanoma
Stage 4
Phase 1
Open to Enrollment
Any
TAC-001
T-cell receptor agonist antibody drug conjugate
Dan Vaena, MD
Tallac Pharmaceuticals
Histologic documentation
CURRENTLY ONLY THE MELANOMA COHORT IS ENROLLING
Inclusion Criteria:
Exclusion Criteria:
A Phase Ia/Ib, Open Label, Multicenter, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors
VIEW TRIAL ON CLINICALTRIALS.GOVEsophageal, Gastric, Cervical, clear cell renal cell cancer, RCC, hepatocellular carcinoma, HCC, liver cancer, HNSCC, head and neck cancer, oropharyngeal, larynx, hypopharyngeal, oral cavity, melanoma, urothelial carcinoma, bladder cancer, triple-negative breast cancer, TNBC, non-small cell lung cancer, NSCLC, colon, prostate
Stage 4
Phase 1
Open to Enrollment
>1st line
RO7502175
Anti-CCR8 antibody
Dan Vaena, MD
Genentech, Inc.
Carcinoma